2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

neutralizing antibodies

" in MedChemExpress (MCE) Product Catalog:

52

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

2

Biochemical Assay Reagents

3

Peptides

49

Inhibitory Antibodies

12

Natural
Products

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9917
    Tocilizumab
    Maximum Cited Publications
    23 Publications Verification

    Anti-Human IL6R, Humanized Antibody

    		 Interleukin Related Inflammation/Immunology Cancer
    Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis . Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease) .
    Tocilizumab
  • HY-P99275
    Patritumab
    1 Publications Verification

    Human Anti-ERBB3 Recombinant Antibody

    		 EGFR Akt ERK PARP Survivin Cancer
    Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
    Patritumab
  • HY-P9945
    Mepolizumab

    SB 240563

    		 Interleukin Related Cardiovascular Disease Inflammation/Immunology
    Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
    Mepolizumab
  • HY-P9945A
    Mepolizumab (anti-IL5)

    		Interleukin Related Inflammation/Immunology
    Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
    Mepolizumab (anti-IL5)
  • HY-122907
    JNJ4796

    		Influenza Virus Infection
    JNJ4796 is an oral active fusion inhibitor of influenza virus, neutralizing influenza A group 1 viruses by inhibiting hemagglutinin (HA)-mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs) .
    JNJ4796
  • HY-P99604
    Cilgavimab

    AZD-1061; COV2-2130

    		 SARS-CoV Infection
    Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .
    Cilgavimab
  • HY-P99937
    Elipovimab

    		HIV Infection
    Elipovimab is a potent broadly neutralizing HIV-1 antibody for the targeted elimination of HIV-infected cells
    Elipovimab
  • HY-153235
    COVID-19 Spike Protein mRNA-LNP

    		SARS-CoV Liposome Infection
    COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) containing mRNA encoding COVID-19 Spike Protein , suitable for detection of RNA delivery, translation efficiency, cell viability, etc. COVID-19 Spike Protein is the novel coronavirus pneumonia spike protein located on the membrane surface. COVID-19 Spike Protein undertakes the functions of virus binding to host cell membrane receptors and membrane fusion, thereby mediating the entry of COVID-19 virus into cells. COVID-19 Spike Protein is an important site of action for host neutralizing antibodies and a key target for vaccine design .
    COVID-19 Spike Protein mRNA-LNP
  • HY-P99710
    Lomtegovimab

    BI 767551; DZIF-10c

    		 SARS-CoV Infection
    Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .
    Lomtegovimab
  • HY-P4020
    2F5 epitope

    		HIV Others
    2F5 epitope, a peptide gp41 (659-671), comprises the entire epitope for one of the three known antibodies capable of neutralizing a broad spectrum of primary HIV-1 isolates and is the only such epitope that is sequential. 2F5 epitope is recognized by broadly neutralizing antibodies 2F5 .
    2F5 epitope
  • HY-P99347
    Etesevimab

    CB 6; JS016

    		 SARS-CoV Angiotensin-converting Enzyme (ACE) Infection
    Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody .
    Etesevimab
  • HY-P99305
    Metelimumab
    1 Publications Verification

    CAT-192; Anti-TGFB1 Recombinant Antibody

    		 TGF-β Receptor Inflammation/Immunology
    Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that can selectively neutralize TGFβ1 .
    Metelimumab
  • HY-147392
    CXCR2 antagonist 8

    		CXCR Metabolic Disease
    CXCR2 antagonist 8 is a potent and selective CXCR2 antagonist. CXCR2 antagonist 8 can be used for insulin resistance research .
    CXCR2 antagonist 8
  • HY-D0871
    CHES

    N-Cyclohexyltaurine

    		 Biochemical Assay Reagents Others Cancer
    CHES (N-Cyclohexyltaurine) is a zwitterionic buffer. CHES can bind to hemagglutinin (HA) emulating with sialic acid (SA) and receptor binding site (RBS)-targeting broadly neutralizing antibodies .
    CHES
  • HY-P99703
    Libivirumab

    17.1.41

    		 HBV Infection
    Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .
    Libivirumab
  • HY-P99307
    Namilumab

    AMG-203; Anti-Human CSF2 Recombinant Antibody

    		 c-Fms Inflammation/Immunology
    Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis .
    Namilumab
  • HY-P99947
    Rimteravimab

    XVR011

    		 SARS-CoV Infection
    Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2 .
    Rimteravimab
  • HY-P99889
    Romlusevimab

    BRII-198

    		 SARS-CoV Infection
    Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
    Romlusevimab
  • HY-P99900
    Sevirumab

    MSL-109

    		 CMV Infection
    Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL .
    Sevirumab
  • HY-P99811
    Rafivirumab

    CR57

    		 RABV Infection
    Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .
    Rafivirumab
  • HY-P9804
    Anti-MERS-2E6 mAb

    MERS-2E6; MERS Antibody-2E6

    		 SARS-CoV Infection
    Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein to the receptor (CD26), thereby inhibiting virus invasion into host cells.
    Anti-MERS-2E6 mAb
  • HY-P9998
    Semzuvolimab

    UB421

    		 HIV Cancer
    Semzuvolimab is a murine IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Murine CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection .
    Semzuvolimab
  • HY-P99792
    Ormutivimab

    NM57; rhRIG

    		 RABV Infection
    Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .
    Ormutivimab
  • HY-P99750
    Navivumab

    CT-P23

    		 Influenza Virus Infection
    Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2 .
    Navivumab
  • HY-P99626
    Frovocimab

    LY 3015014

    		 PCSK9 Metabolic Disease
    Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .
    Frovocimab
  • HY-P99584
    Suvizumab

    KD-247

    		 HIV Infection
    Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection .
    Suvizumab
  • HY-P9953
    Certolizumab pegol

    Certolizumab; CDP870

    		 TNF Receptor Inflammation/Immunology Cancer
    Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .
    Certolizumab pegol
  • HY-P99424
    Afasevikumab

    RG 7624; RO 5553110; NI-1401

    		 Interleukin Related Inflammation/Immunology
    Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities .
    Afasevikumab
  • HY-P99137
    Anti-Mouse IFNAR1 Antibody (MAR1-5A3)

    		IFNAR Inflammation/Immunology
    Anti-Mouse IFNAR1 Antibody (MAR1-5A3) is a neutralizing antibody of IFNAR1. Anti-Mouse IFNAR1 Antibody (MAR1-5A3) reacts with IFNAR1 and inhibits IFNAR1 signaling in vitro and in vivo. Mouse IgG1 kappa, Isotype Control (HY-P99977) is the isotype control of Anti-Mouse IFNAR1 Antibody (MAR1-5A3) .
    Anti-Mouse IFNAR1 Antibody (MAR1-5A3)
  • HY-P99020
    Fresolimumab
    1 Publications Verification

    GC1008

    		 TGF-β Receptor Inflammation/Immunology Cancer
    Fresolimumab (GC1008) is a high-affinity fully human monoclonal antibody that neutralizes the active form of human TGFβ1, TGFβ2, and TGFβ3. Fresolimumab can be used for the research of cancer and fibrotic diseases .
    Fresolimumab
  • HY-P99192
    Emibetuzumab

    LY2875358

    		 c-Met/HGFR Cancer
    Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer .
    Emibetuzumab
  • HY-P99556
    Tixagevimab

    AZD8895

    		 SARS-CoV Infection
    Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .
    Tixagevimab
  • HY-P99368
    Lacnotuzumab

    MCS110; Anti-Human B7-H3

    		 c-Fms Metabolic Disease Cancer
    Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .
    Lacnotuzumab
  • HY-P99103
    Bebtelovimab

    LY-3853113; LY-COV1404

    		 SARS-CoV Infection
    Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .
    Bebtelovimab
  • HY-P99486
    Briakinumab

    ABT-874

    		 Interleukin Related Inflammation/Immunology
    Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .
    Briakinumab
  • HY-P99756
    Nirsevimab

    MEDI8897

    		 RSV Infection
    Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
    Nirsevimab
  • HY-P99417
    Abrezekimab

    UCB4144; VR 942

    		 Interleukin Related Inflammation/Immunology
    Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma .
    Abrezekimab
  • HY-P4042
    Hepatitis B Virus Receptor Binding Fragment

    hepatitis B peptide 4980

    		 HBV Infection Inflammation/Immunology
    Hepatitis B Virus Receptor Binding Fragment (hepatitis B peptide 4980) is a synthetic peptide analog which specifically binds to Hep G2 cells. Hepatitis B Virus Receptor Binding Fragment is a promising immunogen expected to elicit protective antibodies based on the concept of the attachment blockade pathway of virus neutralization .
    Hepatitis B Virus Receptor Binding Fragment
  • HY-P99100
    Visugromab
    1 Publications Verification

    CTL-002

    		 PD-1/PD-L1 Cancer
    Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors .
    Visugromab
  • HY-P9806
    Anti-MERS-D12 mAb

    MERS-D12; MERS Antibody-D12

    		 SARS-CoV Infection
    Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding .
    Anti-MERS-D12 mAb
  • HY-P99395
    Talacotuzumab

    JNJ 56022473; CSL 362

    		 Interleukin Related Cancer
    Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
    Talacotuzumab
  • HY-P9949
    Reslizumab

    Sch 55700

    		 Interleukin Related Inflammation/Immunology
    Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .
    Reslizumab
  • HY-P99588
    Stamulumab

    MYO-029

    		 TGF-β Receptor Metabolic Disease
    Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .
    Stamulumab
  • HY-108810
    Canakinumab

    Ilaris; ACZ 885

    		 Interleukin Related Inflammation/Immunology Cancer
    Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .
    Canakinumab
  • HY-P99551
    Tosatoxumab

    KBSA301; AR-301

    		 Antibiotic Infection
    Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .
    Tosatoxumab
  • HY-P9924
    Ixekizumab

    LY2439821

    		 Interleukin Related Inflammation/Immunology
    Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis .
    Ixekizumab
  • HY-P99340
    Sotrovimab
    1 Publications Verification

    VIR 7831

    		 SARS-CoV Infection Cancer
    Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
    Sotrovimab
  • HY-P99583
    Suvratoxumab

    MEDI4893

    		 Bacterial Infection Inflammation/Immunology
    Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
    Suvratoxumab
  • HY-P99111
    Golimumab

    CNTO-148

    		 TNF Receptor Apoptosis Interleukin Related Caspase Inflammation/Immunology Cancer
    Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research .
    Golimumab
  • HY-126360
    Oxazolone

    		TNF Receptor Interleukin Related Inflammation/Immunology
    Oxazolone is a haptenizing agent that induces acute or chronic inflammation of the large intestine and is used to construct models of colitis. Oxazolone can cause Th1/Th2-dependent colitis with weight loss and diarrhea. Oxazolone-induced inflammation can be mitigated by neutralizing anti-IL-4 or anti-TNF-α antibodies or decoy IL-13R2-α-FC proteins .
    Oxazolone

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: